A : Caldwell 's viell' ofthe paranasa l sinuses reveals a large mu cocele ofthe right fro utal sinu s that extends into the contralateral sinus (arrow s). B: Intraopera tive photog raph shows the inetal stent iil place at the right fro nto nasa l du ct. The im et is a postop erat ive \Vatas ' view of the sinuses and the positian ofthe stent. C: Telescopic viell' (4 mm, OO) of the right nasa! cav ity 38 years after surgay S/IOWS the parti ally exc ised middle turb inat e between the uncinate pra cess (up) and the nasa ! septuni (NS) . D: A closer viel\' of the middl e turbinate (MT) and the right middle meatu s SllOWS a pa tent reconstructed jronton asal duet (a rro w).
In 1959, a 43-year-old pregnant woman co mplained of persistent right fro ntal headach es, for which she had taken analges ics and antibiotics. On exa minatio n, the patient had no foc al neu rologic deficit s. Anterio r rhinoscopy showed that the turbin ates were hypertrophied. A Cald well ' s view x-ray of the paranasal sinus showe d a large soft-tissue ma ss in the right frontal sinus that extend ed to the contral ateral side (figure, A). Th e rad iologic appearance of this ex pansive soft-tissue density was co nsistent with that of a fro ntal sinus mucocele. The mucocele was removed from the right frontal sinus via an external approac h with a Lynch incision. Its contents were evac uateel, anel its sae was carefu lly excise el. The mucosa outlining the frontal sinus was not elisturbeel . The right frontonasa l eluct was enlargeel anel cannu lated with a stent fashioneel from a #3 Jackson metal tracheotomy tube (an inner cannul a shorteneel with a metal saw) . The lower enel of the stent was transnasally visualizeel, and its positia n was aelj usteel after the anterior enel of the mielelle turbinate was amputateel. The meta l ste nt was placeel at the right fronto nasal eluct intraoperatively (figure, B). The stent was removeel transnasally 6 weeks later. Postoperatively, the patient was followe el closely. She repor teel that her heaelaches hael reso lveel, anel she hael no further sinonasal co mplaints.
Have your patients swish-and-swallow the sensible sugar-free way
Thirty-eight years after her surgery , the patient returneel with a complaint of otalgia. Nasal eneloscopy with a 4mm, Ootelescope revea leel a well-healeel right nasal cavity (figure, C) . The reeonstrueteel frontonasa l passage was clea rly patent anel lineel with healthy-appearing mueosa (figure, D ). There was an aelhesio n betwee n the right mielelle turbinate anel the laterai nasal wall, but it eliel not interfere with sinonasal funetion. There was no visible seal' from the Lynch incisio n, anel there was no frontal numbness.
This long-term follow up of 38 years illustrates the sueeessful treatme nt of a frontal sinus mueoeele via an external approae h with a Lynch ineision. In 1959, the two treatment options for frontal sinus mucoeele were an externa l approac h with frontonasa l eluet reeo nstruetion anel an osteoplastie proceelure with sinus oblitera tion with fat. Toelay, thanks to the aelvent of funetional sinus surgery, intranasa i eneloseopie removal of such a mucoce le is another option. The suceessful treatment of frontal sinus mucoeele via the transnasal eneloseopie approaeh has been weil eloeum enteel.I Comp uter assis tanee allows for a more preeise anatomie approaeh to the frontal sinus. When such adva neeel teehnology is not ava ilable or when the surgeo n is less experieneeel with eneloseopie frontal sinus surge ry, an external frontal sinusotomy with reeo nstruetion of the frontonasal passage is stiil a safe anel effee tive methoel of exeising a mueoeele (inclueling its sae) of the frontal sinus, as was show n in this ease. Thi s proeeelure is best performeel uneler close eneloseopie observation of the frontal reeess eluring reeo nstruc tion of the frontonasal passage. Streptomyces noursei. It is known to be a mixture, but t he compositian has not been comp letely elueidated. Nystatin A is d osely related to amphoteriein B. Eaeh is a rnacrocyclic laetone containing a ketal ring, an all-trans polyene system, and a mycosamine (3amino -3-deoxy-rhamnose) moiety. Nystatin Ahas a moleeular formu la of C47H7SN017 and a moleeular weig ht of 926 .11. Nystatin USP is a ready-to-use, non-sterile pow der for oral administ rat ion whieh contains no exeipients or preservat ives. It is available in containers of 50 million, 150 million, 500 million, 2 billion, and 5 billian units. Eaeh mg contains a minimum of 5,000 units. CUNICAl PHARMACOLOGY Nystatin probably aets by binding to stero ls in th e eeli membrane of th e fu ngus with a resultant ehange in membrane permeability allowing leakage of intraeellular compane nts. It is absorbed very sparingly fo llow ing oral administratio n, wi t h no deteetable blood levels w hen given in th e recommended doses. Most of the orally administered nystatin is passed unchanged in t he stoo l.
INDICATIONS FOR USAGE For t he treat ment of intestina i and oral eavity infeetions eaused by
Candida (Mo nilia) albicans.
CONTRAINDICATIONS
Hypersensitivity to the drug . ADVERSE REACTIONS Large oral doses of nystat in have oeeasionally produeed diarrhea, gastrointesti nal dist ress, and possible irritation of t he stomaeh th at may result in nausea and vomit ing. DOSAGE AND ADMINISTRATION General Adu its and older chiidren: Add 1/8 teaspoonful (approximately 500,000 units) of Nystatin USP to about 1/2 eup of wa ter and st ir we il. One-eighth teaspoonful of Nystati n USP is equivalent to th e recommended dose for aduits and ehildren of Nystat in Oral Suspension (4 to 6 mL, or 400,000 to 600,000 units). This produet contains no preservatives and therefo re should be used immediate ly after mixing and should not be stored. It is designed for extemporaneous preparation of a single dose at a time .
Infeetions of the oral cavity caused by Candida (Monilia) albicans: Infant s: 200,000 unit s four tim es daily. Children and adults: 400,000 to 600,000 units fo ur ti mes daily (one-half dose in eaeh side of mouth). NOTE : Limited d inieal studies in premature and low birth-w eight infants indieate th at 100,000 units four t imes daily is effeetive. Loeal treatm ent should be contin ued at least 48 hours after perioral sympto ms have disappeared and eultures retum ed to normaI. It is reeomm ended th at t he drug be retained in the mo ut h as long as possible before swallowi ng.
Intestinal candidiasis (moniliasis) Usual dosage: 500,000 to 1 million units (approximate ly 1/8 to 1/4 teaspoonf ul) thr ee times daily. Treat ment should generally be cont inued for at least 48 hours after d inieal cure to prevent relapse. HOW SUPPUED Nystatin USP is supplied in containers of 50 million, 150 million, 500 million, 2 billian and 5 billian units. Product Code Size Approx. Weight (NDC) (Units) (grams) 0574-0404-05 50 million 8.3 -10 0574-0404-15 150 million 25 -30 0574-0404-50 500 million 83 -100 0574-0404-02 2 billian 333 -400 0574-0404 -00 5 billian 833 -1,000 Storage: Store in a refrigerator, T -8°C (36°-46°F). Prot eet from light. Dispense in a tight, light-resistant container. NOTE: The potency of t his produet eannot be assu red for longer t han 90 days afte r th e container is first opened .
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